.Attributes Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ innovative bosom cancer cells and also energetic or even dependable human brain metastases revealed regular intracranial task as well as systemic effectiveness of T-DXd.